Key breakthrough in human cancer treatment! RedMed’s new therapy doubles survival time for “King of Cancers” patients and reduces risk of death by 60%.

```

A historic breakthrough has been achieved in the global field of pancreatic cancer treatment.

The innovative drug Daraxonrasib, developed by RedMed, has, in the latest phase 3 clinical trial, increased the survival time for patients with advanced pancreatic cancer to 13.2 months, nearly doubling the 6.7 months achieved by conventional chemotherapy, with the risk of death significantly reduced by 60%.

This achievement was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, causing top industry experts to stand up in tribute collectively, and is considered a major revolution in the treatment standard for the “King of Cancers”.

Daraxonrasib not only significantly extends patient survival but also surpasses chemotherapy in pain relief and improvement of quality of life, with a lower incidence of side effects and a discontinuation rate of only 1.2%. This therapy has obtained an FDA Priority Review Voucher and is expected to quickly benefit patients worldwide. The market and investors are closely watching its broad-spectrum applicability, with potential expansion to more RAS-driven cancers in the future.

This breakthrough not only upgrades the treatment standard for pancreatic cancer but also brings new ideas for anti-cancer drug development. Continuous inhibition of the active RAS signaling pathway has become a feasible option for advanced tumors; related clinical data have already been submitted to regulatory agencies, and subsequent trials are ongoing. Investors should pay attention to RedMed’s subsequent product pipeline and global market expansion progress.

Ternary Complex “Molecular Glue” Locks Cancer Cells

The innovative mechanism of Daraxonrasib uses the “molecular glue” strategy to precisely inhibit the core driver of cancer cells—the RAS signaling pathway. Over 90% of pancreatic cancer patients have mutations in RAS genes such as KRAS. The RAS protein surface is smooth with no traditional binding sites, and has long been considered “undruggable”.

Daraxonrasib innovatively employs a ternary complex inhibitory mechanism:

After the drug is orally administered and enters the cell, it first binds to the Cyclophilin A (CypA) protein to form a binary complex.
This complex specifically recognizes and binds to RAS(ON) proteins in the active state, i.e., molecules transmitting cancer signals.
The three combine to form a stable ternary complex, which acts as a “lock” to block RAS from sending carcinogenic signals downstream, thereby inhibiting tumor cell proliferation and metastasis.

This mechanism naturally has broad-spectrum coverage, covering wild-type KRAS/NRAS/HRAS and G12/G13/Q61 mutant subtypes, suitable for most advanced pancreatic cancer patients and other RAS-driven tumors.

Survival Doubled, Death Risk Reduced by 60%

According to NEJM, ASCO annual meeting, and official data, Daraxonrasib demonstrated significant efficacy in the phase 3 RASolute 302 global multicenter randomized controlled trial:

Participants: 500 previously treated metastatic pancreatic cancer patients, 91.8% with RAS G12 mutations.
Overall Survival (OS): Median OS in the Daraxonrasib group was 13.2 months, compared to 6.7 months in the chemotherapy group, HR=0.40, P<0.001.
Progression-Free Survival (PFS): Median PFS in the Daraxonrasib group was 7.2 months, compared to 3.6 months in the chemotherapy group, HR=0.49, P<0.001.

Objective Response Rate (ORR): 31.6% in the Daraxonrasib group, compared to 11.2% in the chemotherapy group, P<0.0001.
Death Risk: Death risk reduced by 60% in the Daraxonrasib group (HR=0.40).
Pain and Quality of Life: Daraxonrasib significantly delayed pain worsening (9.2 months vs 5.7 months), and quality-of-life decline also lasted longer (3.8 months vs 2.6 months), HRs were 0.51 and 0.60 respectively.

Side Effects Are Controllable, Discontinuation Rate Far Lower Than Chemotherapy

Regarding safety, all patients in the Daraxonrasib group experienced adverse events after treatment, mainly mild skin rash and gastrointestinal reactions.

The chemotherapy group had an adverse event incidence rate of 97.7%, including fatigue, anemia, etc.

Daraxonrasib’s ≥ Grade 3 adverse event rate (43.6%) was lower than chemotherapy (57.5%), with a discontinuation rate of only 1.2%, far lower than the 11.2% in the chemotherapy group. Most side effects can be managed by dose adjustment or standard drug management, with no unexpected safety risks observed.

New Standard Drives Industry Upgrade, Broad Applicability Brings Growth Potential

Daraxonrasib has received an FDA Priority Review Voucher and is expected to accelerate its marketing process.

Industry generally believes this drug may become the new standard treatment for previously treated metastatic pancreatic cancer. Its broad-spectrum applicability and innovative mechanism are expected to expand to other RAS-driven tumors in the future, bringing broader market space. RedMed’s product pipeline and global market expansion progress are worthy of investors’ close attention.

Daraxonrasib’s clinical breakthrough marks a new stage in human anti-cancer drug development. Continuous inhibition of the active RAS signaling pathway brings hope to pancreatic cancer patients for doubled survival and drastically reduced risk of death.

With accelerated regulatory approval and ongoing trials, RedMed and the associated industry chain are expected to see a new round of growth. Investors should focus on therapy implementation, expansion of indications, and global market developments.

Risk Warning and DisclaimerThe market has risks, and investments should be made cautiously. This article does not constitute personal investment advice and has not considered the unique investment objectives, financial situation, or needs of individual users. Users should decide whether any opinions, viewpoints, or conclusions in this article are suitable for their specific situation. Invest accordingly at your own risk. ```